Aushon BioSystems Appoints Industry Veteran Susan Vogt Chief Executive Officer

Aushon BioSystems announced the appointment of Susan Vogt as chief executive officer. Vogt brings more than 30 years of experience in the global life science research, pharmaceutical, biotech and clinical diagnostics markets to her new role. Founder and former CEO Pete Honkanen will assume the role of chief operating officer and continue as a board director.

Vogt's experience includes leadership roles at both small and large private and public companies. Most recently, Vogt led the turnaround of diagnostics reagents company SeraCare Life Sciences as president and CEO, where she successfully re-listed the company on NASDAQ and returned the company to growth and profitability. Previously, Vogt held numerous senior level positions at Millipore Corporation, including corporate officer and president of the company’s biopharmaceutical division. She currently serves as non-executive director of TAP BioSystems, and has previously served on the board of directors and advisory boards of a number of other private and publicly-held companies. Vogt holds an MBA from Boston University and a BA from Brown University.

“With sound technology, an elegant, easy-to-use platform and a strong customer base, Aushon is well-positioned to lead the market as the demand for multiplexing in the life sciences continues to grow,” said Vogt. “Our technology enables research that’s critical to the development of both therapeutics and diagnostics, and I look forward to driving the company’s future growth.”

Aushon provides a suite of multiplex immunoassay products and services for the discovery and development of the biomarkers necessary to enable personalized medicine innovation. Multiplexing involves simultaneously measuring and comparing multiple proteins – an improvement over today’s standard which measures one at a time. Fueled by a growing market for multiplexing, Aushon recently announced an anticipated 30 percent year-over-year revenue growth in 2013 and added Thomas Mac Mahon, former president and CEO of Laboratory Corporation of America® Holdings (LabCorp®), to its board of directors.

“Susan is joining Aushon at an exciting time, as we’re expanding to meet increasing demand for our technologies and services by pharmaceutical, biotech and other life sciences research organizations,” said Honkanen. “Her appointment is further evidence of Aushon’s momentum in helping our customers drive the development of new tests and therapies, enabling personalized medicine and, ultimately, better healthcare for patients.”